Reads: 415  | Likes: 0  | Shelves: 0  | Comments: 0

  • Facebook
  • Twitter
  • Reddit
  • Pinterest
  • Invite

Status: Finished  |  Genre: Romance  |  House: Booksie Classic


We are all too far up to see, what is happening in Indian Pharmaceutical Industry because from that High Up, It is a small place to watch; we can have bird’s eye view to see it all but mention few in this audition. First, we will start with GPI.


The global Pharmaceutical industry had reaped about a trillion dollars in 2015 albeit with stagnated growth in the developed market. As a result, Global Pharmaceutical industry has increasingly turned to emerging markets for new growth, profit, and opportunities.

By 2019, GPI will be heading to a stretch of 1.8 trillion dollars. This will be possible only when if the race for new biological products are strategically emanated on the scheduled timeline.


In 2014, eight of the ten best-selling drugs were biological products with combined revenue of $70 billion, 84% of the combined revenue of the top ten drugs. IMS projected that the biological markets would grasp 20% of global pharmaceutical market share by 2018.

Current eloquence among industry experts is that branded biological products will not suffer huge revenue losses after patent expiration due to the difficulty in producing their generic versions.

Additionally, tight complex regulations and high manufacturing cost present other hurdles for their generic rivals to clear. Consequently, pharmaceutical companies are in the chase for novel biosimilars, which already dominate, and are swiftly becoming the first-line option in many key therapy areas.


Out of 80 years of India’s post-independence, for the first 35 years of our life, the food industry had tried to make us fat. Then, the second 35 years, the pharmaceutical industry has tried us for everything with the poor quality of drugs.

The Indian Pharmaceutical Industry is well sizably grown up but unloved.

In this present global quandary, where does India stand? India is a fast emerging economy with the population of 1.325 billion, population growth rate: 1.25 annual change, the fertility rate of 2.40 birth per woman, the life expectancy of 69 years. With this, we have a humongous internal market to 300 products from one company, 10 divisions. What a greedy. 

The pharmaceutical industry in India ranks 3rd in the world terms of volume and 14th in terms of value. India’s cost of production is nearly 33 percent lower than that of the US

Labor costs are 50–55 percent cheaper than in Western countries. The cost of setting up a production plant in India is 40 percent lower than in Western countries. 

This is the main reason MNC are outsourcing on one front and their Governments are banning our products on the other front.

The Indian Pharmaceutical industry, which is expected to grow by over 15 percent per annum between 2015 and 2020. This is because of Indian strong growing economy, but not from R & D, or new innovations. Cost-efficiency continues to create opportunities for Indian companies in emerging markets & Africa. India has a skilled workforce as well as high managerial & technical competence in comparison to its peers in Asia growing per capita sales of pharmaceuticals in India offers ample opportunities for players in this market.


The value of small-molecule products facing a loss of patent expiry in developed markets from 2014 to 2018 is estimated at $121 billion, compared to $154 billion from 2009 to 2013. The BRIC nations (Brazil, Russia, India, and China) are among rising centers of generic activity. Therefore, there is a prediction that the global generics market to reach $533 billion from 2016-2021.

The UN-backed Medicines Patent Pool has signed six sub-licenses with some Indian companies, allowing them to make generic anti-AIDS medicine Tenofovir, Alafenamide for 112 developing countries. Economic prosperity would improve affordability for generic drugs in the market & improve per capita sales of pharmaceuticals in India.

India is a destination for Generic drugs out-sourcing but not for R & D.


While Europe, American and Australian continent eradicated or minimize many of diseases such as dengue fever, typhoid, hepatitis, Jaundice, tuberculosis, malaria, leptospirosis, diarrheal diseases, dysentery, Cholera, worm infestation, and pneumonia, but these diseases continue to plague us.

Most of our studies are based on Indian urban demographic studies. We had not studied upcountry and tribal demographics, which may give altogether a new picture, can be worse than the presented statistics.

Talking of transmitting diseases like HIV/ AIDS, India is ranked third highest among countries with HIV-infected patients.

Nutritional deficiencies: There is a great deal of concern about Indian female, Geriatric, motherhood and childhood diseases and nutritional deficiencies. So, there is and will be a tremendous upward mobility aimed at Indian healthcare and pharmaceutical marketing for all age group patients in all walks of life.

Today, nearly 40 percent of a senior's healthcare spending is on pharmaceutical medications. The reason is, until 2 years back, Alcohol, tobacco, and pharmaceutical banned drugs were legal in India, so they could have hurt the whole lot of people.

With these and other unalone ailments, India is having its potential domestic market. But unfortunately, we have neither patent nor do have a list of research-oriented candidate molecules and new biological products. This is a mammoth negative point.


Adding fuel to fire, the medical profession has become the worst greedy and sold to pharmaceutical industry.  The worst sufferers are patients, especially poor and middle-class patients, as their literacy is insufficient to apprehend healthcare and pharmaceutical tricks.

SUBSTANDARD BRANDS: Mushrooms are known for the contribution of certain medicinally valued ingredients. In India, pharmaceutical companies are mushrooming up as a cottage industry. Our ancestors and modern scientists have identified several dozen mushrooms that have a unique combination of talents that improve our health. But mushroomed Indian Pharmaceutical companies are killing patients with substandard and irrational combinations.

LET US RAISE THE LOCAL STANDARDS: The companies are trying to improve their standards and this issue can be solved by having officials who are more stringent and inspections on a regular basis can be done.

It started with the emergence of India as a favorite destination for “chemistry” outsourcing. The next step in the evolution was collaborative drug discovery as “contract agencies” where the in-house strengths in the chemistry of local companies were augmented with focused biology.  When we committed to make money and ignore fundamental, principles and basic techniques to augment R & D, we will be nowhere in Global Pharmaceutical industry.

R & D:

Indian R & D is an underdog story. Our pharmaceutical companies R & D units are for eyewash and tax benefit in the larger context.  What have we explored of diseases? What discovery and development of agents, we have invented? What have we found, and which has a specific impact on specific disease, with the mode of action or mechanisms and how it provides therapeutic benefit?

I am talking of fundamentals in layman’s language. How many R & Ds are strategically started, intrinsically achieved milestones and how R  & Ds function continued, how many were closed for last 20 years?

By all probabilities, R&D in India is very embarrassing and huge climb down.

How many R & D associates can firmly, solemnly, sincerely and truly tell, what they achieved true threshold discoveries, if not major. In a way, the MNCs and Western counties are blocking our R & D growth. Indian top companies are trying for approval of USFDA, which is important because, to the USA, India is a major exporter. The opinion of the USFDA is considered to be the standard in the sector as well. Let us introspect, how many times, FDA and EMA had banned the import of products from so-called great Indian companies and suspected & blacklisted them because of manufacturing violations.

On the upfront of small and generic drug manufacturing level, we cannot meet global manufacturing capabilities and molecule standards.

Testifying upon Indian research and development, I sincerely feel, Indian pharmaceutical companies cannot prevail upon greater challenges with regard to biological products are concerned, as biosimilars and biologics are more intricate and problematic to develop, characterize, and manufacture than traditional small molecules. Biological products are generally far less stable than small molecule drugs. There will be numerous challenges in every step of biological development; novel excipients, analytics, and technologies are needed to aid biological discovery.

The greatest handicap for Indian Pharmaceutical industry is the poorest-technical entrepreneurship; Irrational combinations, Central and State governments lackadaisical insolence to very ethics of apothecary, uncared attitude towards the suffering of patients, greedy and low quality amid worst competition, encouraging pharmaceutical manufacturing as a cottage industry, and outsourcing to novice professionals and greenhorn manufacturers. In India, Money, and power silenced watchdog bodies. Doctors are increasingly gulled by the lobbying of Medico-marketing personnel.

The whole process is the act of dancing death to patients.

Because of aforesaid anomalies, the genuinely qualified entrepreneurial professionals are unable to start companies, the sufferers deplored inability to express, lamented for government non-interference, and citizens are watching but remain as silent spectators.

I shall continue with my audition. Bye for now.

Submitted: June 25, 2018

© Copyright 2020 thai prasad. All rights reserved.

  • Facebook
  • Twitter
  • Reddit
  • Pinterest
  • Invite

Add Your Comments: